Six years after the initial outbreak of COVID-19, a significant portion of the New Zealand population continues to struggle with the lingering effects of the virus. New data from the latest New Zealand Health Survey reveals that approximately 401,000 adults—about one in 11—are experiencing symptoms of long COVID lasting three months or longer.
These findings highlight a growing public health crisis where the prevalence of long COVID in New Zealand has reached a scale that demands a coordinated government response. According to the survey, 77.7% of New Zealanders, or roughly 3.3 million people, have contracted the virus at least once. Of those who developed the condition following the acute phase of infection, nearly half (48.5%) were still experiencing symptoms at the time of the survey.
As a physician, I have seen how these “invisible” illnesses can dismantle a person’s quality of life. The data suggests This represents not a rare occurrence but a systemic burden. In medical terms, a “rare disease” is typically defined as affecting one in 2,000 people. With a prevalence rate of 9.2% across the general adult population, long COVID is more than 100 times more common than the threshold for rare diseases, necessitating specialized health services and dedicated resources.
Despite the scale of the impact, the release of this data was not proactive. The findings, based on data collection completed in 2025, were only made public following a request under the Official Information Act. This delay in transparency mirrors a broader lack of a formalized government strategy to treat and support those living with the condition.
Who is most affected by long COVID?
The burden of long COVID is not distributed evenly across the population. The survey reveals stark disparities based on gender, ethnicity, and existing health status, suggesting that certain groups are disproportionately vulnerable to lasting complications.
| Group | Prevalence Rate | Estimated Impact |
|---|---|---|
| Women | 14.9% | Approx. 1 in 7 |
| Men | 8.5% | Approx. 1 in 12 |
| Māori Adults | 15.5% | Approx. 1 in 6 |
| Non-Māori Adults | 11.3% | Approx. 1 in 9 |
| People with Disabilities | 22.8% | Approx. 1 in 4 |
The data indicates that women are significantly more likely to report symptoms than men, though this gap disappears among those over the age of 65. The higher prevalence among Māori adults and people living with disabilities underscores the need for equitable healthcare access and targeted support for marginalized communities who may already face systemic barriers to care.
The clinical reality: Beyond ‘Brain Fog’
While the public often associates long COVID with “brain fog”—clinically known as cognitive dysfunction—the condition is a multisystem disorder. It can impact nearly every major organ system, including the cardiovascular, immune, and nervous systems.
Patients frequently report a triad of debilitating symptoms: profound fatigue, cognitive impairment, and post-exertional malaise (PEM), where symptoms worsen after even minimal physical or mental effort. However, the danger is not always symptomatic. There is evidence of “silent” organ damage—cellular and tissue changes that occur without immediate symptoms but may predispose individuals to chronic diseases later in life.
The risk is not static. Research indicates that the likelihood of developing long COVID increases with each subsequent reinfection. With New Zealand currently navigating its ninth wave of COVID-19, the pool of affected individuals is expected to grow, further straining a healthcare system that has yet to implement a tailored care model for these patients.
The cost of institutional inaction
For over a year, health advocates and medical experts have urged the government to establish a coordinated response. This proposed framework includes the creation of specialized treatment and support services, a comprehensive information campaign to educate the public, and targeted surveillance to track the disease’s progression.
The current lack of a formal plan results in a double loss: a decline in individual health and a significant hit to national productivity as thousands of working-age adults locate themselves unable to maintain full-time employment. While some new treatment approaches are showing promise, they cannot be scaled without institutional backing.
Prevention remains the most effective tool. Evidence suggests that vaccination continues to provide a meaningful reduction in both the severity of acute infection and the subsequent risk of developing long COVID. Basic public health measures—such as promoting a culture of staying home when sick and improving indoor air quality through ventilation and filtration—could significantly reduce the number of new cases.
Necessary steps for a national recovery plan
- Specialized Care: Establishing multidisciplinary clinics for symptom management and rehabilitation.
- Financial Safety Nets: Creating targeted support for those whose long COVID symptoms prevent them from working.
- Public Health Infrastructure: Investing in high-standard indoor air quality and UV lighting in public settings to reduce viral transmission.
- Ongoing Research: Funding local studies to understand the specific needs of Aotearoa’s diverse population.
Disclaimer: This article is provided for informational purposes only and does not constitute medical advice. Please consult a healthcare professional for diagnosis and treatment of any health condition.
The evidence is clear: COVID-19 remains a major infectious disease in New Zealand. While the public may be reluctant to discuss the pandemic in the present tense, the data confirms that the aftermath is a current and pressing reality. The next critical checkpoint will be the government’s response to the 2025 health survey data and whether Health New Zealand will finally move from passive data collection to active clinical intervention.
We want to hear from you. If you are living with long COVID, how has the lack of a formal government plan affected your care? Share your experience in the comments or share this article to raise awareness.
